[1] Rockstroh JK,Spengler U,Sudhop T,et al.Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV.Am J Gastroenterol,1996,91:2563-2568.
[2] Brau N,Salvatore M,Rios-Bedoya CF,et al.Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.J Hepatol,2006,44:47-55.
[3] European Association for the Study of the Liver.EASL Recommendations on Treatment of Hepatitis C 2015.J Hepatol,2015,63:199-236.
[4] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of hepatitis C virus infection.J Hepatol,2011,55:245-264.
[5] Schinazi R,Halfon P,Marcellin P,et al.HCV directacting antiviral agents:the best interferon-free combinations.Liver Int,2014,34(Suppl.1):69-78.
[6] Kwo P,Gitlin N,Nahass R,et al.Aphase 3,randomized,openlabel study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir(SMV)plus sofosbuvir(SOF)in treatment-na ve and experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1.50th International Liver Congress(ILC),April 22-26,Vienna,Austria;abstract LP14.
[7] Molina JM,Orkin C,Iser DM,et al.All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes1,2,3 and 4 infection in patients co-infected with HIV (PHOTON-2).AIDS2014.20th International AIDS Conference.July 20-25,2014.Melbourne.Abstract MOAB0105LB.
[8] Naggie S,Cooper C,Saag MS,et al.Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1.22nd Conference on Retroviruses and Opportunistic Infections,February 23-26,2015,abstract 152LB.
[9] Wyles DL,Ruane PJ,Sulkowski MS,et al.ALLY-2 Investigators.Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.N Engl J Med,2015,373:714-725.
[10] Sulkowski MS,Eron JJ,Wyles D,et al.Ombitasvir,paritaprevir codosed with ritonavir,dasabuvir,and ribavirin for hepatitis C in patients co-infected with HIV-1:a randomized trial.JAMA,2015,313:1223-1231.
[11] Sulkowski MS,Naggie S,Lalezari J,et al.Sofosbuvir and ribavirin for hepatitis C in patients with HIV-1 coinfection.JAMA,2014,312:353-361.
[12] Molina JM,Orkin C,Iser DM,et al.All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV geno-types 1,2,3 and 4 infection in patients co-infected with HIV(PHOTON-2).AIDS2014.20th International AIDS Conference.July 20-25,2014.Melbourne.Abstract MOAB0105LB.
[13] ALLY-3 Study Team.,Nelson DR,Cooper JN,Lalezari JP,et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virusgenotype3infection:ALLY-3phaseIII study.Hepatology,2015,61:1127-1135.
[14] Pawlotsky JM.Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.Gastroenterology,2016,151:70-86.
[15] Marks K,Weinberg EM,Kumar S,et al.Sofosbuvir,simeprevir,+/ribavirin in HCV protease inhibitor-experienced patients.22nd Conference on Retroviruses and Opportunistic Infections,abstract,644,2015.
[16] Lau G,Benhamou Y,Chen GF,et al.Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection:a phase 2,open-label,proof-ofconcept study.Lancet Gastroenterol Hepatol,2016,1:97-107. |
